Lipid Solubility and Drug Penetration of the Blood Brain Barrier
about
Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme TreatmentCardiac output and the blood pressure increase in deoxycorticosterone acetate-salt hypertension after nicotine infusionImage-guided convection-enhanced delivery platform in the treatment of neurological diseases.Drug transfer across the blood-brain barrier and improvement of brain delivery.How to measure drug transport across the blood-brain barrierComparison of lipid-mediated blood-brain-barrier penetrability in neonates and adults.Newborn rabbit blood-brain barrier is selectively permeable and differs substantially from the adult.Design of iron chelators with therapeutic application.Design of clinically useful iron(III)-selective chelators.Nicotine and cotinine concentrations in serum and milk of nursing smokers.Immunotoxin therapy for CNS tumor.The CNS as a target for peptides and peptide-based drugs.Metals ions and neurodegeneration.Delivery of peptides to the brain: emphasis on therapeutic development.Drug disposition in the mammalian eye and brain: a comparison of mechanisms.Characterization of a Novel Nicotine Degradation Gene Cluster ndp in Sphingomonas melonis TY and Its Evolutionary Analysis.The potential application of iron chelators for the treatment of neurodegenerative diseases.Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40.Synthesis and in vitro anti-HIV activities of didanosine prodrugs.Phenytoin: basic and clinical pharmacology.Nicotine transdermal systems.Drug transport across the blood-brain barrier. III. Mechanisms and methods to improve drug delivery to the central nervous system.The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system.Permeability of ergot alkaloids across the blood-brain barrier in vitro and influence on the barrier integrity.Equilibration, distribution, and elimination of a single dose of intravenous ethanol in dogs with intact renal function or anuria.Interactions of beta-amyloids with the blood-brain barrier.Intravenous phenytoin and phenobarbital: anticonvulsant action, brain content, and plasma binding in rat.Regional blood-brain barrier transport of the steroid hormones.A double-radionuclide autoradiographic method using N-isopropyl-iodoamphetamine for sequential measurements of local cerebral blood flow.Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System.Intranasal dopamine application increases dopaminergic activity in the neostriatum and nucleus accumbens and enhances motor activity in the open field.The effect of single cerebroside compounds on activation of BKCa channels.The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.[Changes in the blood-cerebrospinal fluid barrier for serum proteins in children with acute lymphatic leukemia].Cerebral uptake of nicotine and of amino acids.Isotope effect studies on the dehydrogenation of delta 1-tetrahydrocannabinol in the rat.SU-8 based microprobes for simultaneous neural depth recording and drug delivery in the brain.Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.Biophysical Properties and Antiviral Activities of Measles Fusion Protein Derived Peptide Conjugated with 25-Hydroxycholesterol.
P2860
Q26773083-1FD97A72-E972-4574-A22B-6BAA9EF50C76Q28335520-32C730D2-9868-4174-9DD5-79686E2CA92DQ31141544-CC263C82-2C50-4C1A-B51C-578DBD9A674CQ33535027-E9776E25-01CB-4479-BF66-16401A385B46Q33985116-4F23A11A-265A-43B9-9A8E-94E78B28ADFDQ34056959-6C79C532-2A8E-4B2D-8B9C-BF2432D88EBAQ34057546-86C6B871-C986-4E01-992B-ACA42DB612E8Q34258805-DF871CCA-BD13-4177-950C-E76F8B3A656DQ34464580-0A689EB3-CEB8-43CC-B181-169783B353A4Q34621728-DF6F9DA5-B018-4917-8954-8E1CACF10324Q35210454-D8C5A2F0-00D4-4BE6-B13D-82211C741837Q36640307-4B1B313D-13A3-4879-944C-AEFCFED3E78DQ36733713-9D3A20E8-47B0-40FC-BE34-BE6210B2155EQ37107996-8A1C0D22-E3C9-4529-9A84-E80C9F547A3AQ37238136-BA81F21C-5CFA-4814-9524-8895F9648487Q37689553-981F7DA4-EFD7-4BD1-BAA9-F4962A04FF84Q37846107-10DAE49E-F087-4F57-8A43-F9F77036E4E9Q39216411-FD0AF246-45B8-4817-AC06-C7CF46633258Q40156661-A10E59E5-DD6F-4861-9C99-BEF1E3983D8AQ40164017-B1804789-D8C7-4604-8D1B-2F1F6652C781Q40824648-CC474CB2-399E-41BA-8C74-225A75FC9FFBQ40903092-0B5AA685-C070-4DD1-A816-C96C0401C98AQ41170052-8B145657-F365-4428-8CCD-FE233CEB950BQ41232282-EB2BEFC9-6E4D-4D2A-BC40-BA7F4D111A61Q41353684-3C9499B2-9D40-4648-A687-287F2BB9E05CQ41451033-A003DABE-C9DF-4C39-9F9E-7BF93BD2837FQ41611063-697D2C59-C1B0-412F-8D5F-3A8E9EA7C95CQ41621106-49D27242-2693-4693-952C-DC471947DBABQ41743191-1547ECF7-908D-4BEB-A3C3-FE71D2324DDBQ42218289-3B0572CE-E931-4FC1-82DC-323A876AFFE6Q42362521-EE41E613-47B3-4194-AA7E-B2F89DCD88F5Q42639744-42D46483-03FD-4668-ACFB-E660E8C54F91Q42684637-4C6DB05F-6B7D-4236-B4C1-8842B838B0CFQ43069428-EA4C4643-5920-4752-A3D1-42C714233A76Q44801941-0E5F4397-F580-470A-B4AB-1FF1C15FC4A9Q44814676-5FD0C0D5-06A3-4E45-BF6E-9616C9ABA801Q45113502-7058B141-AFFC-428E-875C-1909D18543D2Q45279827-DA39A1FE-C8C5-48DB-A1B0-8255A2EBEE93Q46041559-B26F8050-7EA7-4705-8BFB-2CE67DE592D5Q47582990-C43A480B-5CFE-4D26-81A9-CE2826CA3AAD
P2860
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
description
im Dezember 1974 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1974
@uk
name
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@en
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@nl
type
label
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@en
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@nl
prefLabel
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@en
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@nl
P1476
Lipid Solubility and Drug Penetration of the Blood Brain Barrier
@en
P2093
W. H. Oldendorf
P304
P356
10.3181/00379727-147-38444
P577
1974-12-01T00:00:00Z